Nov 12, 2019 Yield10 Bioscience Announces Third Quarter 2019 Financial Results WOBURN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today reported financial results for the three and nine months ended September 30, 2019. https://yield10bioscienceinc.gcs-we...cience-announces-third-quarter-2019-financial Recent Progress Achieving 2019 Milestones Expanded the research agreement with Bayer for evaluation of a new discovery related to the C3004 yield trait gene in soybean. Under the amended research license, Bayer will have access to new developments from Yield10’s C3004 program based on advanced technology related to the C3004 trait and its potential to increase seed yield. Signed a research agreement with J. R. Simplot Company, to evaluate novel new traits to produce high yielding, sustainable potato crop. Under the agreement with Yield10, Simplot plans to conduct research with three yield traits (C3003, C3004, C4001) within its research and development program as a strategy to improve crop performance and sustainability. In addition to the three-year, non-exclusive research agreement, Simplot was granted an option to negotiate an exclusive commercial license agreement. Presented research showcasing the Camelina Platform for producing PHB biomaterials to improve water quality. At the 3rd International Conference on Plant Synthetic Biology held in October, Yield10’s CSO Dr. Kristi Snell highlighted the scientific breakthrough achieved by Yield10 researchers demonstrating the ability to produce PHB biomaterials at the level of 10% of the mature seed weight in seeds of Camelina. PHB-producing Camelina can improve the sustainability of food production as a cover crop, by mitigating nutrient runoff at its source in the field, while also producing a PHB product for use as a denitrifying agent for water treatment that provides revenue to the farmer.
Bought a first position today at the end of the day and will likely continue to add to my position depending on the share price development. Current market cap equals the current cash. The cash at hand is expected to fund the operations into the second quarter of 2021. This should provide the company sufficient time to achieve some milestones which can boost the share price.
Yield10 Bioscience Secures Regulatory Permits for U.S. and Canadian Sites and Announces Plans for 2020 Field Test Program in Camelina and Canola May 14, 2020 http://ir.yield10bio.com/node/15136/pdf
I am looking to re-enter in this one. Imo there will be good entry points in the coming days. YTEN'S technolgy is great and the stock is always good for quick spike upon good news. Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement August 23, 2020 WOBURN, Mass., Aug. 22, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, todayannounced the pricing of its underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. The grossproceeds from the public offering will be approximately $3.5 million, before deducting underwriting discounts and commissions and estimated offeringexpenses. In addition, Yield10 also announced that investors affiliated with existing investor Jack W. Schuler, have agreed to purchase 396,450 sharesof Yield10’s common stock pursuant to a securities purchase agreement with Yield10 at the same price per share as in the public offering, in aseparate private placement transaction that is expected to close concurrently with the public offering. The gross proceeds from the private placementwill be approximately $1.7 million. All shares in the public offering and private placement are to be sold by Yield10. http://ir.yield10bio.com/node/15331/pdf
Well, looks like I am too late as I did not have sufficient cash available, damn. It is trading above $8 in pre-market today...
